India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Women and older adults using semaglutide, a popular anti-obesity medication, may face a heightened risk of muscle loss. A recent study suggests that women and older adults who use the weight-loss drug ...

Table of Contents The Real Story Behind Your Changing Body Making Every Bite Count When You’re Eating Less Your Brain […] The ...

Dr. Reddy’s Laboratories (NYSE:RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...

A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...

Can it really be maintained after they’re discontinued on top-selling drugs such as Ozempic or Wegovy, or is rebound weight gain simply a natural part of the process? For many adult patients taking ...

The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.